Gait characteristics in patients with type 2 diabetes; improvement after administration of rosiglitazone.

Background: Gait is impaired in people with type 2 diabetes. An insulin sensitizer, rosiglitazone(RSG) has promise to reverse some of the circulatory impairments seen in diabetes. The hypothesis to be tested was if RSG would improve gait in patients with diabetes.